The FDA has officially approved Kresladi, a gene therapy aimed at treating a rare immune disorder. This decision follows a small-scale trial that included only nine patients.
The trial's results were reported as positive, indicating potential efficacy in addressing the specific immune condition targeted by Kresladi.
This approval marks a significant step in gene therapy applications, although the limited patient sample size necessitates cautious interpretation of the findings.